Drug targets in Leishmania
Leishmaniasis is a major public health problem and till date there are no effective vaccines available. The control strategy relies solely on chemotherapy of the infected people. However…
Leishmaniasis is a major public health problem and till date there are no effective vaccines available. The control strategy relies solely on chemotherapy of the infected people. However…
Paromomycin is currently in phase IV clinical trials against leishmaniasis. In the present work we elucidate the effect and mechanism of uptake of paromomycin in Leishmania donovani. …
Madhubala–the very name conjures up vivid images of a love goddess possessing … of the ‘reel life’Madhubala but also of the ‘real life’Madhubala, who was an extremely compassionate …
Objectives The resistance of clinical isolates of Leishmania donovani to sodium antimony gluconate (SAG), the mainstay of treatment in Indian visceral leishmaniasis, has become a …
INTRODUCTION: The aim of this study was to evaluate and compare the antimicrobial activity of calcium hydroxide, triantibiotic mixture (TAM), and an ethanol extract of propolis as …
Leishmania donovani is a protozoan parasite that causes visceral leishmaniasis (VL) and is responsible for significant mortality and morbidity. Increasing resistance towards antimonial …
Microorganisms isolated from stressed ecosystem may prove as ideal candidates for development of bio‐inoculants for stressed agricultural production systems. In the present study, …
Leishmania donovani is an obligate intracellular parasite that infects macrophages of the vertebrate host, resulting in visceral leishmaniasis in humans, which is usually fatal if untreated…
The exponential rise in the development of cloud computing environments in the healthcare field, the protection and confidentiality of the medical records become a primary concern for …
Ternary laminated Fe 2 AlB 2 alloy holds its significance in displaying high strength, damage tolerance, oxidation and radiation cracking resistance. It is synthesized through a …